Structure via PubChem · Public domain (PubChem)
lomitapide
Sign in to saveAlso known as AEGR-733, BMS-201038, Juxtapid®, Lojuxta®, BMS 201038, AEGR 733
Lomitapide , sold under the brand name Juxtapid in the US and Lojuxta in the EU, is a medication used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals. It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.
Chemical data
- Formula
- C39H37F6N3O2
- Molecular weight
- 693.7 g/mol
- IUPAC name
- N-(2,2,2-trifluoroethyl)-9-[4-[4-[[2-[4-(trifluoromethyl)phenyl]benzoyl]amino]piperidin-1-yl]butyl]fluorene-9-carboxamide
- SMILES
- C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
- InChIKey
- MBBCVAKAJPKAKM-UHFFFAOYSA-N
- XLogP
- 8.6
- Polar surface area
- 61.4 Ų
- H-bond donors
- 2
- H-bond acceptors
- 9
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2012
- Admin. routes
- oral
- Indications
- cardiovascular disease, familial hypercholesterolemia, homozygous familial hypercholesterolemia
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 693.279
- Has use
- medication
Show 8 more facts
- medical condition treated
- lipedema
- chemical formula
- C₃₉H₃₇F₆N₃O₂
- canonical SMILES
- C1CN(CCC1NC(=O)C2=CC=CC=C2C3=CC=C(C=C3)C(F)(F)F)CCCCC4(C5=CC=CC=C5C6=CC=CC=C64)C(=O)NCC(F)(F)F
- World Health Organisation international non-proprietary name
- lomitapide
- defined daily dose
- 40
- Commons category
- Lomitapide
- physically interacts with
- Microsomal triglyceride transfer protein
- significant drug interaction
- itraconazole
via Wikidata · CC0
~2 min read
Encyclopedic overview
4 sectionsContents
- Mechanism of action
- Side effects
- References
- External links
Lomitapide , sold under the brand name Juxtapid in the US and Lojuxta in the EU, is a medication used as a lipid-lowering agent for the treatment of familial hypercholesterolemia, developed by Aegerion Pharmaceuticals. It has been tested in clinical trials as single treatment and in combinations with atorvastatin, ezetimibe and fenofibrate.
The US Food and Drug Administration (FDA) approved lomitapide in December 2012, as an orphan drug to reduce LDL cholesterol, total cholesterol, apolipoprotein B, and non-high-density lipoprotein (non-HDL) cholesterol in people with homozygous familial hypercholesterolemia (HoFH).
Excerpted from Wikipedia’s “lomitapide” article, available under the CC BY-SA 4.0 licence.